Sino Biological Introduces ProPure™ Endotoxin-Free Proteins, Enhancing Research and Therapeutic Development
Sino Biological US, Inc. launches ProPure™, a line of ultra-pure, endotoxin-free recombinant proteins produced in the USA, setting a new industry standard for research and therapeutic applications.
Sino Biological US, Inc. has announced the launch of ProPure™, a groundbreaking line of ultra-pure, endotoxin-free recombinant proteins, manufactured at its Center for Bioprocessing (C4B) facility in Houston, Texas. This innovation is poised to significantly impact immunology research, vaccine development, and therapeutic protein manufacturing by providing products with endotoxin levels below the limit of quantification (LOQ).
The ProPure™ proteins are developed using advanced purification technologies and mammalian expression systems, ensuring high purity for sensitive applications where endotoxin contamination could jeopardize results or patient safety. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized the company's dedication to scientific excellence and product safety, highlighting the potential of ProPure™ to support breakthroughs in both basic and translational science.
This launch reflects Sino Biological's commitment to bioprocessing innovation and its support for the global life sciences community. Beyond standard offerings, the C4B facility also offers customized protein development services to meet specific research and production needs. For more information, visit https://www.sinobiological.com.